---
title: "kfsyscc-of-Enfortumab vedotin"
slug: "kfsyscc-of-enfortumab-vedotin"
date: "2023-11-26"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[Enfortumab vedotin]]

# kfsyscc-of-Enfortumab vedotin

- Padcev powder for infusion 30 mg/24kg enfortumab vedotin/vial å‚™æ€å¾©å‡æ™¶æ³¨å°„åŠ‘ IENFO3 (è‡¨æŽ¡)
- å¸¸ç”¨åŠ‘é‡
  - Urothelial cancer, locally advanced or metastatic, combination therapy:
  - IV: 1.25 mg/kg (maximum dose: 125 mg) on days 1 and 8 every 21 days (in combination with pembrolizumab) until disease progression or unacceptable toxicity
  - Urothelial cancer, locally advanced or metastatic, single-agent treatment:
  - IV: 1.25 mg/kg (maximum dose: 125 mg) on days 1, 8, and 15 every 28 days until disease progression or unacceptable toxicity
- åŠ‘é‡èª¿æ•´
  - Dosage in renal impairment: No dosage adjustment necessary.
  - Dosage in hepatic impairment: Moderate to severe impairment (total bilirubin >1.5 times ULN and any AST): Avoid enfortumab vedotin use.
- è‡ªè²»åƒ¹æ ¼ 30055/24kg = 90000/72kg
